Hyalex Orthopaedics, a Lexington, MA-based medical device company advancing new products that feature a novel polymer system that is intended to mimic cartilage, raised additional funding in an expansion of its original Series A.
New investors Strategic Healthcare Investment Partners and DSM Venturing, the venture arm of Royal DSM, joined existing investors Canaan, Osage University Partners and Johnson & Johnson Innovation – JJDC Inc. (JJDC).
The Series A funding now totals $33MM.
The funding will support the development of its platform.
Led by President and CEO Mira Sahney, Hyalex Orthopaedics is a medical device company advancing new products that feature HYALEX™ materials technology, a polymer that is designed to mimic cartilage. Unlike other polymers, synthetic HYALEX material has the capability of maintaining low friction and low wear under the high loads encountered in human joints.
Hyalex Orthopaedics’ products are in the development stage and have not been approved for use in humans by any regulatory agency.
Source. Company Press Release, March 28, 2019
Note. This post was brought to you by Woewoda Communications, your partner in the private equity and startup markets; offering strategic communications, public relations & investor relation services to VCs, PEs, Angels, Endowments/Trusts, Family Offices, and Startups involved in ICT, IoT, blockchain, life sciences, healthcare, agribusiness, clean energy, fintech, AI and robotics.
No comments:
Post a Comment